NICE Final Draft Guidance Recommends Improved Access To Psoriatic Arthritis Treatments

Three treatments for psoriatic arthritis are recommended in final draft guidance published by the National Institute of Health and Clinical Excellence (NICE). Etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) are proposed for treating adults with active and progressive psoriatic arthritis when specified criteria are met...